Ignite Creation Date:
2024-05-06 @ 12:04 PM
Last Modification Date:
2024-10-26 @ 12:53 PM
Study NCT ID:
NCT03664635
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-04-23
First Post:
2018-09-03
Brief Title:
MB-CART201 Lymphoma
Sponsor:
Miltenyi Biomedicine GmbH
Organization:
Miltenyi Biomedicine GmbH
Study Overview
Official Title:
A Phase III Safety Dose Finding and Feasibility Trial of MB-CART201 in Patients With Relapsed or Resistant CD20 Positive B-NHL
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial is a phase III trial to assess safety dose finding and feasibility of ex vivo generated MB-CART201 cells in patients with relapsed or refractory CD20 positive B-NHL
Detailed Description:
MB-CART201 consists of autologous Anti-CD20 Chimeric Antigen Receptor CAR transduced CD4 CD8 enriched T cells targeting CD20-positive tumor cells in Non-Hodgkin-Lymphoma NHL
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None